BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
Of all the major crosstown streets—Canal, Houston, 14th—none may be as commercial as 42nd, especially its central strip. Wide ...
of patients treated with ensartinib reached 24-month disease-free survival, compared to 53.5% in the placebo control arm.
Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...
The agency’s decision to conceal drug names on inspection reports has prevented doctors, pharmacists and patients from ...
Janet McCaskill was on vacation in Arizona with her husband and best friend when she heard that President Donald Trump had ...
Read here for an analysis of Thermo Fisher (TMO) stock's Q3 2024 growth, major stock buyback, and how Fed rate cuts boost ...
From Montenegro to Northern California, the tech elite dream of building cities where they make the rules. Is this, finally, ...
Zacks Investment Research on MSN
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space. Oncology or ...
The deal comes as AI firms take increasing amounts of space in New York City’s office market. AI companies leased almost ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback